CD8A and neoplasm: BNT111 is a leading candidate targeting melanoma tumor-associated antigens in a current phase II trial which previously showed induction of both CD4+ and CD8+ T-cell responses in 78% of patients, both alone and in combination with cemiplimab, a PD-1 inhibitor [75].